THOMAS LYNCH JR., director of Yale Cancer Center and physician-in-chief of Smilow Cancer Hospital at Yale-New Haven, will leave Yale in August to become chairman and chief executive officer of the Massachusetts General Physicians Organization.
Schulam to Serve as Interim Director of Yale Cancer Center as Lynch Plans to Step Down
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on print
Table of Contents
YOU MAY BE INTERESTED IN
In a year that brought us new KRAS-inhibiting drugs, deepened our understanding of HER2 in breast cancer, and highlighted new potential for mRNA vaccines, the cancer field was also rocked by uncertainty of the future of research funding, equity in cancer delivery, and the integrity of review at FDA.


A year like 2025 has demanded a lot from all of us, between the Trump administration’s flooding of the zone, the impact of DOGE and MAHA initiatives on the National Cancer Program, and the personal toll of living amidst uncertainty. In many ways, 2025 was a test. Did the field of oncology pass? Did The Cancer Letter?


As trust in scientific and regulatory institutions frays and the meaning of “gold standard science” is increasingly contested, cancer research faces a credibility test of its own.


Earlier this month, NCI released a new Cancer Center Support Grant Notice of Funding Opportunity. Except for the elimination of the Plan to Enhance Diversity component and lengthening of the Shared Resource write-ups from three to six pages, the guidelines are essentially unchanged.


New Year’s Eve approaches, and with it, a chance to turn a new leaf with renewed energy, to reflect on—or perhaps, in the case of 2025, bemoan—the events of the year, and, most importantly, to celebrate.





